Literature DB >> 26647441

Oestradiol metabolism and androgen receptor genotypes are associated with right ventricular function.

Corey E Ventetuolo1, Nandita Mitra2, Fei Wan2, Ani Manichaikul3, R Graham Barr4, Craig Johnson5, David A Bluemke6, Joao A C Lima7, Hari Tandri7, Pamela Ouyang7, Steven M Kawut8.   

Abstract

Sex hormones are linked to right ventricular (RV) function, but the relationship between genetic variation in these pathways and RV function is unknown.We performed a cross-sectional study of 2761 genotyped adults without cardiovascular disease. The relationships between RV measures and single nucleotide polymorphisms (SNPs) in 10 candidate genes were assessed. Urinary oestradiol (E2) metabolites produced by cytochrome P4501B1 (CYP1B1) and serum testosterone were measured in women and men respectively.In African-American (AA) women, the CYP1B1 SNP rs162561 was associated with RV ejection fraction (RVEF), such that each copy of the A allele was associated with a 2.0% increase in RVEF. Haplotype analysis revealed associations with RVEF in AA (global p<7.2×10(-6)) and white (global p=0.05) women. In white subjects, higher E2 metabolite levels were associated with significantly higher RVEF. In men, androgen receptors SNPs (rs1337080; rs5918764) were significantly associated with all RV measures and modified the relationship between testosterone and RVEF.Genetic variation in E2 metabolism and androgen signalling was associated with RV morphology in a sex-specific manner. The CYP1B1 SNP identified is in tight linkage disequilibrium with SNPs associated with pulmonary hypertension and oncogenesis, suggesting these pathways may underpin sexual dimorphism in RV failure.
Copyright ©ERS 2016.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26647441      PMCID: PMC4831135          DOI: 10.1183/13993003.01083-2015

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  48 in total

1.  Right ventricular function in heart failure with preserved ejection fraction: a community-based study.

Authors:  Selma F Mohammed; Imad Hussain; Omar F AbouEzzeddine; Omar F Abou Ezzeddine; Hiroyuki Takahama; Susan H Kwon; Paul Forfia; Véronique L Roger; Margaret M Redfield
Journal:  Circulation       Date:  2014-11-12       Impact factor: 29.690

2.  Sex-dependent influence of endogenous estrogen in pulmonary hypertension.

Authors:  Kirsty M Mair; Audrey F Wright; Nicholas Duggan; David J Rowlands; Martin J Hussey; Sonia Roberts; Josephine Fullerton; Margaret Nilsen; Lynn Loughlin; Matthew Thomas; Margaret R MacLean
Journal:  Am J Respir Crit Care Med       Date:  2014-08-15       Impact factor: 21.405

3.  Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease.

Authors:  D A Morrison; K Adcock; C M Collins; S Goldman; J H Caldwell; M I Schwarz
Journal:  J Am Coll Cardiol       Date:  1987-06       Impact factor: 24.094

4.  Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy.

Authors:  Mariëlle C van de Veerdonk; Taco Kind; J Tim Marcus; Gert-Jan Mauritz; Martijn W Heymans; Harm-Jan Bogaard; Anco Boonstra; Koen M J Marques; Nico Westerhof; Anton Vonk-Noordegraaf
Journal:  J Am Coll Cardiol       Date:  2011-12-06       Impact factor: 24.094

5.  Pulmonary hypertension surveillance--United States, 1980-2002.

Authors:  Alexandra Hyduk; Janet B Croft; Carma Ayala; Kan Zheng; Zhi-Jie Zheng; George A Mensah
Journal:  MMWR Surveill Summ       Date:  2005-11-11

6.  Testosterone, cytochrome P450, and cardiac hypertrophy.

Authors:  Thomas Thum; Jürgen Borlak
Journal:  FASEB J       Date:  2002-10       Impact factor: 5.191

7.  Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females.

Authors:  E D Austin; J D Cogan; J D West; L K Hedges; R Hamid; E P Dawson; L A Wheeler; F F Parl; J E Loyd; J A Phillips
Journal:  Eur Respir J       Date:  2009-04-08       Impact factor: 16.671

8.  Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol.

Authors:  J J Michnovicz; H L Bradlow
Journal:  Nutr Cancer       Date:  1991       Impact factor: 2.900

9.  Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.

Authors:  Kevin White; Anne Katrine Johansen; Margaret Nilsen; Loredana Ciuclan; Emma Wallace; Leigh Paton; Annabel Campbell; Ian Morecroft; Lynn Loughlin; John D McClure; Matthew Thomas; Kirsty M Mair; Margaret R MacLean
Journal:  Circulation       Date:  2012-08-02       Impact factor: 29.690

10.  Testosterone negatively regulates right ventricular load stress responses in mice.

Authors:  Anna R Hemnes; Karen B Maynard; Hunter C Champion; Linda Gleaves; Niki Penner; James West; John H Newman
Journal:  Pulm Circ       Date:  2012-07       Impact factor: 3.017

View more
  20 in total

1.  Oestrogen inhibition reverses pulmonary arterial hypertension and associated metabolic defects.

Authors:  Xinping Chen; Eric D Austin; Megha Talati; Joshua P Fessel; Eric H Farber-Eger; Evan L Brittain; Anna R Hemnes; James E Loyd; James West
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 2.  New and Emerging Therapies for Pulmonary Arterial Hypertension.

Authors:  Edda Spiekerkoetter; Steven M Kawut; Vinicio A de Jesus Perez
Journal:  Annu Rev Med       Date:  2018-09-14       Impact factor: 13.739

3.  Inhibiting oestrogen signalling in pulmonary arterial hypertension: sex, drugs and research.

Authors:  Tim Lahm; Steven M Kawut
Journal:  Eur Respir J       Date:  2017-08-03       Impact factor: 16.671

Review 4.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

Review 5.  Pulmonary Arterial Hypertension and the Sex Hormone Paradox.

Authors:  Andrew Foderaro; Corey E Ventetuolo
Journal:  Curr Hypertens Rep       Date:  2016-11       Impact factor: 5.369

6.  Role of the Aryl Hydrocarbon Receptor in Sugen 5416-induced Experimental Pulmonary Hypertension.

Authors:  Afshan Dean; Teja Gregorc; Craig K Docherty; Katie Y Harvey; Margaret Nilsen; Nicholas W Morrell; Margaret R MacLean
Journal:  Am J Respir Cell Mol Biol       Date:  2018-03       Impact factor: 6.914

Review 7.  Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension.

Authors:  David F Condon; Stuti Agarwal; Ananya Chakraborty; Natasha Auer; Rocio Vazquez; Hiral Patel; Roham T Zamanian; Vinicio A de Jesus Perez
Journal:  Chest       Date:  2021-10-13       Impact factor: 9.410

8.  Anastrozole in Pulmonary Arterial Hypertension. A Randomized, Double-Blind, Placebo-controlled Trial.

Authors:  Steven M Kawut; Christine L Archer-Chicko; Angela DeMichele; Jason S Fritz; James R Klinger; Bonnie Ky; Harold I Palevsky; Amy J Palmisciano; Mamta Patel; Diane Pinder; Kathleen J Propert; K Akaya Smith; Frank Stanczyk; Russell Tracy; Anjali Vaidya; Mary E Whittenhall; Corey E Ventetuolo
Journal:  Am J Respir Crit Care Med       Date:  2017-02-01       Impact factor: 21.405

Review 9.  Novel signaling pathways in pulmonary arterial hypertension (2015 Grover Conference Series).

Authors:  Keytam S Awad; James D West; Vinicio de Jesus Perez; Margaret MacLean
Journal:  Pulm Circ       Date:  2016-09       Impact factor: 3.017

Review 10.  Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Authors:  Arunabh Talwar; Joe G N Garcia; Halley Tsai; Matthew Moreno; Tim Lahm; Roham T Zamanian; Roberto Machado; Steven M Kawut; Mona Selej; Stephen Mathai; Laura Hoyt D'Anna; Sonu Sahni; Erik J Rodriquez; Richard Channick; Karen Fagan; Michael Gray; Jessica Armstrong; Josanna Rodriguez Lopez; Vinicio de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.